The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis

Research output: Contribution to journalArticle

39 Downloads (Pure)

Abstract

The pathological hallmarks of Systemic sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of vascular endothelial growth factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential vascular endothelial growth factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.

Original languageEnglish
Pages (from-to)99-109
JournalCurrent Rheumatology Reviews
Volume15
Issue number2
Early online date9 Aug 2018
DOIs
Publication statusPublished - 2019

Fingerprint

Systemic Scleroderma
Vascular Endothelial Growth Factor A
Protein Isoforms
Precision Medicine
Disease Management
Autoimmunity
Disease Progression
Fibrosis
Pathology
Therapeutics

Cite this

The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis. / Flower, Victoria A; Barratt, Shaney L; Ward, Stephen; Pauling, John D.

In: Current Rheumatology Reviews, Vol. 15, No. 2, 2019, p. 99-109.

Research output: Contribution to journalArticle

@article{93e1fee53d48488db431e5916780cab9,
title = "The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis",
abstract = "The pathological hallmarks of Systemic sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of vascular endothelial growth factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential vascular endothelial growth factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.",
author = "Flower, {Victoria A} and Barratt, {Shaney L} and Stephen Ward and Pauling, {John D}",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2019",
doi = "10.2174/1573397114666180809121005",
language = "English",
volume = "15",
pages = "99--109",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis

AU - Flower, Victoria A

AU - Barratt, Shaney L

AU - Ward, Stephen

AU - Pauling, John D

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2019

Y1 - 2019

N2 - The pathological hallmarks of Systemic sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of vascular endothelial growth factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential vascular endothelial growth factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.

AB - The pathological hallmarks of Systemic sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of vascular endothelial growth factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential vascular endothelial growth factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.

U2 - 10.2174/1573397114666180809121005

DO - 10.2174/1573397114666180809121005

M3 - Article

VL - 15

SP - 99

EP - 109

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 2

ER -